CEOs to defend prices before House committee

Top executives of six biopharma companies will be called to testify before the U.S. House Committee on Oversight and Reform next week to explain their drug pricing strategies.

“These companies sell medications that are critical to our health and well-being, but their skyrocketing prices are simply unsustainable,” Rep. Carolyn Maloney, chair of the committee, said in announcing the two-day hearings.

Read more